Cure First

A precise path to healthier and more effective cancer treatments. We're so much closer to a cure than the medical field once thought possible!

Our organization is currently doing groundbreaking research that will revolutionize the way the medical industry treats and cures cancer without the use of chemotherapy or radiation. By utilizing unique functional genomics, robotics instruments, computational tools, and high-throughput screening methods, Cure First can change the world! Our research team is currently conducting research projects onnew drug combinations for ovarian cancer and neuroblastoma. We are also focusing on four of the most the aggressive subtypes of cancer - head and neck squamous cell carncinoma, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. With success in the clinical trials of treating and curing two of these cancers that previously had no known treatment or therapies, we’re hopeful for what the future has in store! There are plans to expand screening into ovarian and childhood cancer types that are also in the works. We've had significant success thus far in utilizing novel drugs to treat and target carcinomic genomes. Cure First's research and applications have been found that targeting specific carcinomic genomes leads not only to tumor regression in preclinical models, but that health and life of non-carcinoma surrounding cells can simultaneously be improved. We hope that you'll join us on our journey to finding a cure for cancer... You're helping us change the world. Together we can find a cure!

04/07/2023

Dear Cure First Friends and Supporters,

As you are aware we have been fundraising to help Szymon Sawicki obtain crucial personalized vaccines to fight his stage 3 Pancreatic Adenocarcinoma. This cause is very important for Szymon and his family because these novel approaches are not yet reimbursed by insurance.

Your support to date has been crucial to cover a portion of the expenses associated with the vaccine, which costs $80,000. Cure First has contributed an initial deposit of $20,000 from its existing funds and, with your contributions, together we have raised an additional $5,321.

Szymon still needs your help in reaching his fundraising goal of an additional $54,679.

Would you be willing to make a contribution to Szymon’s campaign? A gift of any amount would get Szymon closer to receiving life-saving treatment . The vaccine will be ready at the end of April and will be administered monthly. Syzmon’s oncologist is ready for Szymon to receive the first injection.

To donate, simply click the link to Szymon’s campaign below:

https://www.curefirst.org/specialcampaign-szymon-sawicki

Please share Szymon’s story and this fundraiser link with everyone you know. The more eyes on Szymon’s campaign, the better!

Thank you in advance for any and all contributions.

I was diagnosed with stage 3 Pancreatic Adenocarcinoma in September of 2021. My wife, Jeannie, has spent countless hours researching the best tools and therapies to keep this terrifying disease at bay. For anyone who doesn't know, the average survival time for a patient with stage 3 Pancreatic Cance...

12/15/2022

Thanks to all who have contributed to our campaign to help medical experts personalize a pancreatic cancer vaccine for Szymon Sawicki. You can read more about Szymon and donate here: https://www.curefirst.org/specialcampaign-szymon-sawicki. Help us continue to raise funds by choosing Cure First as your designated 501c3 nonprofit when you make purchases on Amazon. We are grateful for your support.

12/03/2019

Thank you for your continued support of our commitment to find more effective and less toxic treatments for children with neuroblastoma. Your contributions today will allow us to continue our research and help us share our findings at the upcoming Advances in Neuroblastoma Research conference this May in Amsterdam.

curefirst.org/donate-2

11/16/2019

NATIONAL PHILANTHROPY DAY

Help us help others.

Your donations will advance our efforts to develop more effective and less toxic treatments for patients with neuroblastoma and ovarian cancer.

http://curefirst.org/donate-2

Thank you,
The Cure First Team

10/02/2019

Xander is why we do the work we do. He has high-risk neuroblastoma. Cure First is dedicated to finding safe and effective treatments for this childhood cancer.

"Xander started chemotherapy immediately to battle the cancer that had already spread throughout his body. He has a large tumor growing out of his upper back bone as well bone marrow disease and bone lesions in his legs, his pelvis, his spine and his skull.

His diagnosis requires long stints of intense treatment, which has been "difficult" for Xander, his mother and his 3-year-old-sister Olivia...And so far, treatment has not worked."

Xander Bowman lost his hearing during an intense type of chemotherapy.

08/21/2019

We are sad to report the passing of one of our first and most ardent supporters. Dick Robbins was a creative innovator whose generosity fueled our most important advances and aspirations.

Richard James Robbins August 12, 1933 to May 30, 2019 Richard James Robbins was born in 1933 in Grass Valley, California, to James Snowell Robbins a

07/15/2019

PRIME for PERSONALIZED MEDICINE

You can make a difference while you shop Amazon Prime Day deals on July 15 & 16. Simply shop at smile.amazon.com/ch/45-4721229 and AmazonSmile donates to Cure First

When you shop at AmazonSmile, Amazon will donate to Cure First. Support us every time you shop.

06/17/2019

Remembering Barbara McClintock, the only woman to be awarded an unshared Nobel Prize in Physiology or Medicine, who was born on this day in 1902.

McClintock discovered 'jumping genes' in corn, and proved that chunks of genetic code can change position on a chromosome, affecting genetic expression.

Born in Hartford Connecticut, McClintock's family had little money, so her interest in research was viewed with skepticism. It was more important for her to marry, her family thought. Despite this, with her father's support, Barbara began studying at Cornell's College of Agriculture in 1919, and her studies are where her interest remained. She never married, choosing to devote her life to research instead. She was shy and anything but a careerist, but at the same time she also realised the importance of what she had achieved, not least of all in her role as an example for other women.

Learn more about Barbara McClintock and her research: https://bit.ly/2wkb2XH

06/06/2019

In pursuing Cure First’s mission to find new treatments for children with neuroblastoma (NB), Dr. Carla Grandori and lead scientist Rachele Rosati traveled to Philadelphia in April to meet Dr. Maris and his team of NB experts at the Children Hospital of Philadelphia. They discussed respective updates from their laboratories, in particular newly identified NB targeting drugs. We are currently raising funds to test these drugs in vivo, a critical stage before the proposed treatments can head to clinical trials. You can help children with neuroblastoma by supporting this promising research. Donate at curefirst.org.

05/05/2019

Dr. Eddie Mendez was a critical force behind the founding of Cure First. All best to the recipients for this important award.

03/26/2019

The Intersection of Art and Science

The 10 images in this year's exhibit were chosen from more than 160 submissions. They offer a peek into the living world as few have ever seen it.

Address

Seattle, WA

Website

http://www.curefirst.org/

Alerts

Be the first to know and let us send you an email when Cure First posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Cure First:

Shortcuts

Want your practice to be the top-listed Clinic in Seattle?

The Cure First Story

Our organization is performing groundbreaking research that will revolutionize the way the medical field approaches cancer without the use of chemotherapy or radiation. By utilizing functional genomics, robotic instruments, computational tools, and high-throughput screening methods, Cure First is helping realize the potential of precision medicine and personalized cancer treatments. Our research team is currently conducting research projects on new drug combinations for ovarian cancer and neuroblastoma. We are also focusing on some of the most the aggressive subtypes of cancer: head and neck squamous cell carcinoma, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. With success in the clinical trials of treating and curing two of these cancers that previously had no known treatment or therapies, we’re hopeful for what the future has in store! We've had significant success thus far in utilizing novel drugs to treat and target cancer genomes. Cure First's research and applications have found that targeting specific genomes leads not only to tumor regression in preclinical models, but that health and life of non-carcinoma surrounding cells can simultaneously be improved. We hope that you'll join us on our journey. Together we can find a cure!

Visit our website, curefirst.org, to learn more and to donate to our projects.